Leading Skincare AI-Analysis Platform, EveLab Insight, Named Top 5 AI Company to Watch

Through an infusion of AI and evidence-based skin science, EveLab Insights secures its spot on The Silicon Review list.

SINGAPORE / ACCESSWIRE / April 17, 2023 / EveLab Insight, a leading provider of AI-driven skin analysis services, has been named one of the top 5 AI companies to watch by The Silicon Review, a prominent platform for business and technology professionals. This recognition underscores EveLab Insight’s innovative approach to artificial intelligence and its commitment to building a scientific and evidence-based approach to skincare.

Related Image

https://cdn.newswire.com/files/x/19/01/d95a62f292be3a61795ef68dbb9c.jpg

EveLab Insight – 5 Best AI Companies to Watch
EveLab Insight has been named one of the top 5 AI companies to watch by The Silicon Review

Widely praised for its ability to accurately identify and quantify complex skin problems, EveLab Insight’s skin analytics platform utilizes proprietary AI models and the world’s largest image library of dermatologist-labeled skin conditions to detect surface and subsurface skin issues for more than 10 million consumers globally. Working with world-renowned companies such as Dior and Shiseido Effectim, EveLab Insight’s platform helps brands improve product recommendations and innovate their R&D efficacy testing.

EveLab Insight works at the intersection of two key AI sectors: AI-driven analytics and AI-generated content. The AI-driven analytics platform is able to crunch thousands of data points on the human face to build an accurate 3D map that precisely identifies key skin issues that consumers and brands wish to understand at a deeper level. This AI engine is supported by a skin condition image library of more than 10 million dermatologist-labeled photos.

Building upon the facial maps generated by the analytics engine, EveLab Insight’s content engine is able to generate predictive imagery that reflects potential changes in skin conditions over time. Using this information, brand counter-associates can offer more personalized product recommendations backed by science.

Additionally, this predictive engine provides insights that can advance dermatological research and treatments related to skin issues. EveLab Insight is currently working closely with several leading brands to co-develop AI algorithms that better understand a wider variety of skin tones.

Interview Highlights

During the interview with EveLab Insight, the team highlighted that the value of skin detection technology goes beyond the technology itself. It also provides powerful decision-making support for numerous business clients in the beauty industry based on customer insights acquired through this technology. Please click here to see the detailed interview.

EveLab Insight‘s selection as one of the top 5 AI companies to watch by The Silicon Review is a testament to its commitment to innovation and excellence in the field of artificial intelligence. Its AI-driven solutions and personalized skincare recommendations can help beauty brands enhance their operations, R&D, and improve the overall consumer experience, contributing to their growth and success.

Please view our website for more information: www.EveLabInsight.com

Contact Information

Daisy Zhang
Marketing Manager
daisy.zhang@evelabinsight.com

Related Files

An innovator providing a revolutionary experience for beauty and skin care consultations with industry-leading technology and ar

SOURCE: EveLab Insight

 

HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies

HanchorBio Received IND Clearance of HCB101 Multi-regional Clinical Trial By US FDA

TAIPEI, TAIWAN and SAN FRANCISCO, CA / ACCESSWIRE / April 17, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.

Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio, commented, “Although there is demonstrated history of PD-1/PD-L1 immune checkpoint inhibitors showcasing strong efficacy in a variety of cancers and significantly improved the prognosis of certain cancer patients, there is a large percentage of cancer patients who are either refractory to these immunotherapies or develop resistance. HCB101 is our independently-developed leading candidate to block the “do not eat” signal from the SIRPα-CD47 pathway, sufficiently eliminating tumor cells by macrophage while exhibiting excellent safety profile in our preclinical studies. The FDA clearance of our first IND marks a significant milestone for HanchorBio and demonstrates our team’s continuous focus and commitment to bringing novel immunotherapies to patients with significant unmet need.”

“Based on our studies in 15 murine xenograft tumor models of solid and hematological malignancies, HCB101 has demonstrated superior anti-tumor efficacy, both as monotherapy and in combination with other agents. The advantage is even more apparent when comparing HCB101 with other agents targeting the same pathway currently being investigated in clinical trials,” said Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio. “Unlike other CD47-blocking agents, HCB101 exhibits excellent safety profiles in the repeat-dose cynomolgus monkey toxicology studies, as no abnormality of RBC or platelet levels were observed. It is an important safety factor for differentiation. I look forward to advancing the clinical development of HCB101 and continuing the focus on patient-centric research and development to hopefully bring novel treatments with clinically meaningful benefits to patients as early as possible.”

About HCB101

Using structure-guided protein design and engineering supplemented with relevant screening technologies, HCB101 is an engineered extracellular domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers phagocytic activity of the macrophages by blocking the “do not eat” signal between macrophages and tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a safer and more potent biologic than the anti-CD47 monoclonal antibodies and SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment comparing to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action.

About Multi-Regional Clinical Trial of HCB101

HCB101-101 is a multi-regional, multi-center, open-label, dose-finding, first-in-human (FIH) study of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. The purposes of the study are to evaluate the safety, tolerability, pharmacokinetics, and clinical anti-tumor activity of weekly HCB101 intravenous injections. The HCB101 IND is on track being reviewed by the Taiwan FDA.

About HanchorBio

Based in Taipei, Shanghai, and San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with proven track-record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.

For more information, please visit: www.HanchorBio.com

or follow us on LinkedIn at www.linkedin.com/company/hanchorbio-inc

Contact Information

Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com

Yi Du
Sr. Director of Business Development
yi_du@hanchorbio.com


HanchorBio_logo

SOURCE: HanchorBio Inc.

ZeroFox to Acquire LookingGlass, Broadening Global Attack Surface Intelligence Capabilities

Deal strengthens ZeroFox’s External Cybersecurity Platform with industry-leading attack surface management (EASM) and threat intelligence capabilities

WASHINGTON, April 17, 2023 (GLOBE NEWSWIRE) — Today, ZeroFox (Nasdaq: ZFOX), an enterprise software-as-a-service leader in external cybersecurity announced a definitive agreement to acquire LookingGlass Cyber Solutions, Inc., a leader in external attack surface management and global threat intelligence. In today’s digital-first world, the rapidly expanding external attack surface has become a veritable playground for cybercriminals and nation-state actors alike, posing an ever-growing threat to enterprise and public sector organizations worldwide. Integrating LookingGlass’s industry-leading attack surface and threat intelligence capabilities into the ZeroFox External Cybersecurity Platform will enable our customers to build a robust security posture by providing world-class visibility into external attack surface assets and vulnerabilities, including improved actionable intelligence to disrupt emergent threats.

As organizations embrace digital transformation, the same externally-available digital platforms these organizations use to do business are equally available to malicious actors, creating new opportunities for exploitation. This escalating threat landscape underscores the urgent need for organizations to adopt comprehensive security strategies emphasizing proactive monitoring, continuous assessment, and remediation of their public attack surface vulnerabilities to defend against the mounting challenges of persistent cyber adversaries.

“The acquisition of LookingGlass is a natural extension of our strategy to provide our customers with a single end-to-end platform for protecting their external attack surface from increasingly sophisticated cyberattacks,” said James C. Foster, Chairman and CEO of ZeroFox. “We are bringing together passionate teams that have been partners for years, and proven world-class capabilities across attack surface management, digital risk protection, threat intelligence and breach response to continue our leadership in external cybersecurity.”

With one of the most comprehensive internet-facing attack surface intelligence data lakes, LookingGlass empowers public sector organizations, large enterprises, and industry security alliances at scale by providing extensive discovery, intelligence and cyber defense capabilities. These unique capabilities allow organizations to identify and assess threats in support of remediation strategies against the most sophisticated cyberattacks. The combination of intelligence and action enables some of the world’s largest organizations to inform their security teams about cyber risks ahead of full-fledged attacks.

“The mission at LookingGlass is to protect our customers by providing unmatched attack surface intelligence for global threat visibility and cyberattack disruption,” said Bryan Ware, CEO of LookingGlass. “Joining ZeroFox allows us to expand the capabilities we provide security teams to defend against cybercriminals and nation-state actors.” Ware, a cybersecurity industry veteran, former Assistant Director of CISA at the Department of Homeland Security, the Nation’s cyber defense operations lead, will join the ZeroFox executive team as part of the transaction.

Transaction Details

Under the terms of the agreement, ZeroFox will acquire LookingGlass for approximately $26 million, primarily in stock (9.4 million shares), combined with convertible debt and cash, subject to purchase price adjustments and performance earnouts. The acquisition is expected to close within the next 30 days. ZeroFox will provide additional guidance during the Q1 FY24 earnings call.

Stifel Financial Corp. served as exclusive financial advisor to ZeroFox on the transaction.

Investor Conference Call Information

ZeroFox will host a conference call to discuss the acquisition today April 17, 2023 at 8:30 a.m. Eastern Time. To access this call via webcast, please use this link: ZeroFox Business Update. The live webcast and a webcast replay of the conference call can be accessed from the investor relations page of ZeroFox’s website at https://ir.zerofox.com.

Learn More

To learn more about ZeroFox solutions, visit our website. Bookmark the ZeroFox Blog to keep up with our expert coverage on the latest in External Cybersecurity.

About ZeroFox

ZeroFox (Nasdaq: ZFOX), an enterprise software-as-a-service leader in external cybersecurity, has redefined security outside the corporate perimeter on the internet, where businesses operate, and threat actors thrive. The ZeroFox platform combines advanced AI analytics, digital risk and privacy protection, full-spectrum threat intelligence, and a robust portfolio of breach, incident and takedown response capabilities to expose and disrupt phishing and fraud campaigns, botnet exposures, credential theft, impersonations, data breaches, and physical threats that target your brands, domains, people, and assets. Join thousands of customers, including some of the largest public sector organizations as well as finance, media, technology and retail companies to stay ahead of adversaries and address the entire lifecycle of external cyber risks. ZeroFox and the ZeroFox logo are trademarks or registered trademarks of ZeroFox, Inc. and/or its affiliates in the U.S. and other countries. Visit www.zerofox.com for more information.

About LookingGlass Cyber Solutions, Inc.

LookingGlass is the global cybersecurity leader enabling national, industrial, and enterprise-scale decisions with unparalleled, curated intelligence on critical assets, risks, and sectors. For more than a decade, the most advanced organizations in the world have trusted LookingGlass to help them protect their economic and national security interests. Find out how we can help your organization at https://lookingglasscyber.com.

Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future, including statements related to benefits from the transaction, including expected from revenues and accretiveness of the transaction, and the ability of ZeroFox to achieve its objectives and plans with the acquisition of LookingGlass are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. The inclusion of any statement in this press release does not constitute an admission by ZeroFox or any other person that the events or circumstances described in such statement are material. These risks and uncertainties include, but are not limited to, the following: our ability to recognize the anticipated benefits of the transaction; the ability of ZeroFox and LookingGlass to consummate the transaction as expected; defects, errors, or vulnerabilities in the ZeroFox platform, the failure of the ZeroFox platform to block malware or prevent a security breach, misuse of the ZeroFox platform, or risks of product liability claims that would harm our reputation and adversely impact our business, operating results, and financial condition; if our enterprise platform offerings do not interoperate with our customers’ network and security infrastructure, or with third-party products, websites or services, our results of operations may be harmed; we may not timely and cost-effectively scale and adapt our existing technology to meet our customers’ performance and other requirements; our ability to introduce new products and solutions and features is dependent on adequate research and development resources and our ability to successfully complete acquisitions; our success depends, in part, on the integrity and scalability of our systems and infrastructure; we rely on third-party cloud providers to host and operate our platform, and any disruption of or interference with our use of these offerings may negatively affect our ability to maintain the performance and reliability of our platform which could cause our business to suffer; we rely on software and services from other parties; we have a history of losses, and we may not be able to achieve or sustain profitability in the future; if organizations do not adopt cloud, and/or SaaS-delivered external cybersecurity solutions that may be based on new and untested security concepts, our ability to grow our business and our results of operations may be adversely affected; we have experienced rapid growth in recent periods, and if we do not manage our future growth, our business and results of operations will be adversely affected; we face intense competition and could lose market share to our competitors, which could adversely affect our business, financial condition, and results of operations; competitive pricing pressure may reduce revenue, gross profits, and adversely affect our financial results; adverse general and industry-specific economic and market conditions and reductions in customer spending, in either the private or public sector, including as a result of inflation and geopolitical uncertainty such as the ongoing conflict between Russia and Ukraine, may reduce demand for our platform or products and solutions, which could harm our business, financial condition and results of operations; the COVID-19 pandemic could adversely affect our business, operating results, and financial condition; if we fail to adapt to rapid technological change, evolving industry standards and changing customer needs, requirements or preferences, our ability to remain competitive could be impaired; one U.S. government customer accounts for a substantial portion of our revenues; and we rely heavily on the services of our senior management team.

Additional information concerning these, and other risks, is described under the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations of ZeroFox”, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations of IDX” sections of our final prospectus filed with the Securities and Exchange Commission (the “SEC”) pursuant to Rule 424(b) under the Securities Act of 1933 on April 12, 2023, in connection with our registration statement on Form S-1 and in subsequent reports that we file with the SEC. We expressly disclaim any obligation to update any of these forward-looking statements, except to the extent required by applicable law.

ZeroFox Contacts:

Media Inquiries
Malory Van Guilder
zerofox@skyya.com

Investor Relations
Marc P. Griffin, ICR
investor@zerofox.com

GlobeNewswire Distribution ID 8808801

Falcon Autotech Expands Presence in the Middle East with New Office Opening

DUBAI, United Arab Emirates, April 17, 2023 (GLOBE NEWSWIRE) — Falcon Autotech (Falcon) is pleased to announce the opening of its new office in Dubai, UAE, marking a significant milestone in the company’s expansion into the Middle East market. The new location will enable Falcon to better serve its existing customers in the region and expand its reach to new markets and prospects.

The decision to establish a presence in the Middle East was driven by the growing demand for Falcon’s solution in the region, as well as the strategic importance of Middle East as a hub for business and innovation. With a team of experienced professionals based in region, Falcon is well-positioned to support the needs of clients in a wide range of industries, including CEP, eCommerce, Fashion & Retail, FMCG, Auto and Pharma.

“We are thrilled to be opening our new office in Middle East,” said Sandeep Bansal, CBO of Falcon. “This is an exciting opportunity for us to expand our global reach and provide world-class warehouse automation solutions to our customers in the Middle East. We believe that Dubai is the ideal location for us to establish a strong presence in the region, and we look forward to building strong relationships with our clients and partners in the Middle Eastern region.”

Falcon has a long history of delivering innovative warehouse automation solutions and outstanding customer service to clients around the world. With the opening of its new office in Dubai, the company is poised to continue its growth and expand its reach in the Middle East.

For more information about Falcon and its products and services, please visit www.Falconautotech.com

Contact:
Abhishek Kumar
Marketing Manager
Falcon Autotech
Abhishek@falconautoonline.com

About Falcon:
Falcon Autotech is a global intralogistics automation solutions company. With over 10 years of experience, Falcon has worked with some of the most innovative brands in E-Commerce, CEP, Fashion, Food/FMCG, Auto, and Pharmaceutical Industries. With its proprietary software and robust hardware integration capabilities, Falcon designs, manufactures, supplies, implements, and maintains world-class warehouse automation systems globally. Falcon’s strong research and development team and the continuous focus on innovation reflect our strong solution line around Sortation, Robotics, Conveying, Vision Systems, and IoT. Falcon has done over 1,800 installations across 15 countries on 4 continents.

GlobeNewswire Distribution ID 8808835

Apical’s Entry to Sustainable Aviation Fuels Takes Flight with Cepsa to Build the Largest 2G Biofuels Plant in Southern Europe

SINGAPORE – Media OutReach – 17 April 2023 – Apical, through its renewable energy subsidiary Bio-Oils located in Huelva, Spain, has established a joint venture with Cepsa to produce second generation (2G) biofuels by constructing the largest plant in southern Europe. The joint venture will entail an investment of up to €1 billion, one of the largest private investments in the history of the southern Spanish region of Andalusia. The alliance marks Apical’s entry to the sustainable aviation fuels (SAF) market and a key milestone in RGE’s strategy to produce a range of fuels to decarbonise aviation, maritime and land transportation. Apical, a leading vegetable oil processor, is a member of the Singapore-headquartered RGE group of companies.

Photo caption: The new joint venture was announced at La Rábida Energy Park with the participation of Juan Manuel Moreno Bonilla, President of the Regional Government of Andalusia; Maarten Wetselaar, Cepsa CEO (fourth from the left); Oscar Garcia, Bio-Oils CEO (second from the right); Dato’ Yeo How, President, Apical (fourth from the right); Pratheepan Karunagaran, Executive Director, Apical (third from the left); and Lamberto Gaggiotti, Head, Green Energy, Apical (first from the left).

The new plant, which is scheduled to begin operation in H1 2026, can produce up to 500,000 tons of SAF and/or renewable diesel annually, enabling the reduction of CO2 emissions by up to 90 percent, as compared to traditional fuels.

SAF is often viewed as a tool to a zero-emissions future. However, the key global challenge to the production of SAF is access to feedstock (renewable waste and residue raw materials). As a large global integrated processor of vegetable oils, Apical is able to efficiently and sustainably extract waste and residue from its supply chain and its processes in a transparent and traceable manner.

Through the joint venture, the plant will secure the majority of its feedstock supply from Apical’s agricultural waste and residue through a global, long-term agreement. Cepsa will contribute its technical expertise and experience in the development of large industrial projects and fuel production; and knowledge of the European market and the decarbonisation goals of its customers in the transport sector. The facility will be located at Cepsa’s La Rábida Energy Park in the Spanish province of Huelva.

Dato’ Yeo How, President of Apical, said: “Apical’s ample supply of high quality second generation feedstock is key to ensuring that the new joint venture delivers on our shared vision to reduce greenhouse gas emissions across air, sea and land transport. The wider use of SAF and renewable diesel provides significant benefits on a global scale, both in terms of mitigating the effects of climate change and promoting sustainable economic growth. Apical, through Bio-Oils, will ensure the supply of raw materials and contribute our own expertise in biofuels production.”

The new facility will feature the latest technology for the production of second generation biofuels.  Designed as a digital native plant, the new operation incorporates state-of-the-art technology including the latest industry advances in artificial intelligence, internet of things (IoT) and data analysis to maximise process efficiency, and ensure the highest standards of safety and environmental protection.  By leveraging innovation, Apical is accelerating its sustainable operations in line with Apical2030’s Pillar 3 (Green Innovation) of its strategic sustainability roadmap.

Pratheepan Karunagaran, Executive Director, Apical, said: “Aviation emissions account for 2-3 percent of global energy-related CO2 emissions and are expected to grow by 300-700 percent by 2050[1]. To reduce the direct carbon emissions of flying, SAF can be an immediate solution. A next-generation low-carbon fuel produced from 100% renewable waste and residue raw materials, it works seamlessly with existing aircraft engines and fuelling infrastructure.  As the availability of waste and residue grows in tandem with the expansion of Apical’s global footprint and capacities, we are able to create value-added partnerships for our waste stream in various parts of the world, especially in Asia.”

With regard to the development of the SAF industry in Asia, Pratheepan commented: “SAF in Asia has much potential for growth and development.  The good news is: as more countries begin to recognise the importance of sustainable practices and environmental responsibility, there is likely a greater focus on promoting the adoption of SAF throughout the aviation industry,” he added.

Juan Manuel Moreno Bonilla, highlighted in his speech: “Cepsa has been investing in Huelva and Andalusia for almost 60 years and has been an active part and main player in the progress experienced in our land. Cepsa has made an outstanding contribution to our progress and to the creation of employment, with almost 8,000 direct and indirect jobs. Big bets like Cepsa’s confirm that we are on the right track.”

Maarten Wetselaar noted: “This alliance is a decisive step in our strategy to lead biofuels in Spain and Portugal and positions Andalusia as a European benchmark in sustainable energy production and circular economy. Second-generation biofuels are an immediate solution to support our customers’ energy as they can be used in conventional engines, while enabling local development and increased energy autonomy in Europe.”

Oscar Garcia said: “Cepsa has been Bio-Oils’ largest customer for many years. We share many operational advantages, such as the proximity and interconnection of our facilities and the use of the Reina Sofía berth for the charge and discharge of our products. This new joint venture is a natural evolution of our relationship”

Notes to Editors:

Apical is a leading vegetable oil processor with an expanding global footprint. Our vertically integrated mid-stream refining and value-added downstream processing makes us an integral supplier that supports the food, feed, oleochemicals and renewable fuel needs across industries.   With integrated assets in strategic locations spanning Indonesia, China and Spain, Apical operates numerous refineries, oleochemical plants, renewable fuel plants and kernel crushing plants. Through joint ventures and strategic partnerships, Apical also has processing and distribution operations in Brazil, India, Pakistan, Philippines, Middle East, Africa, USA and Vietnam.

Apical’s growth is built on the foundations of sustainability and transparency, and motivated by our strong belief that we can make a more meaningful impact even as we continue to grow our business and deliver innovative solutions to our customers.

Cepsa is a leading international company committed to sustainable mobility and energy with a solid technical experience after more than 90 years of activity. The company also has a world-leading chemicals business with increasingly sustainable operations.

In 2022, Cepsa presented its new strategic plan for 2030, Positive Motion, which projects its ambition to be a leader in sustainable mobility, biofuels, and green hydrogen in Spain and Portugal, and to become a benchmark in the energy transition. The company places customers at the heart of its business and will work with them to help them advance their decarbonization objectives.

ESG criteria inspire all of Cepsa’s actions as it advances toward its net positive objective. Over the course of this decade, it will reduce its Scope 1 and 2 CO2 emissions by 55% and its carbon intensity index by 15-20%, with the goal of achieving net zero emissions by 2050.

Bio-Oils was founded in 2005 to develop biofuels projects, with the strategic objective to become a leading industry player in the Spanish and European biodiesel market.  A member of the Singapore-based Apical group of companies, Bio-Oils´ wholly owned “La Rábida” Biodiesel Plant, located in Palos de la Frontera (Huelva), began operations in 2008 and today is one the most efficient plants in Spain, benefitting from a strategic location, with pipeline connections to vessel and tanker loading docks.

Through an ambitious R&D program, Bio-Oils has obtained wide experience in the production of high-quality biofuels from a broad variety of oils. The plant currently uses all available first-use oils, and has been adapted to process other residual raw materials.  Committed to operating at the highest levels of sustainability, Bio-Oils is a member of APPA (Association of Renewable Energy Producers), FOSFA (Federation of Oils, Seeds and Fats Associations), EBB (European Biodiesel Board), EABA (European Algae Biomass Association), and AIQBE (Association of Chemical Industries, Basic and Energy of Huelva).

RGE, headquartered in Singapore, is a group of resource-based manufacturing companies with global operations. We produce sustainable natural fibres, edible oils, green packaging and clean natural gas used to create products that feed, clothe and energise the world. We help improve billions of peoples’ lives through sustainable products they use every day. With more than US$30 billion in assets and 60,000 employees, we are creating a more recyclable, biodegradable and lower carbon future.

Committed to sustainable development, conservation and community development, we strive towards what is good for the community, good for the country, good for the climate, good for the customer, and good for the company. With current operations spanning across Indonesia, China, Brazil, Spain and Canada, we continue to expand and engage new markets.

Media Contact

Lim Siow Joo
E: siowjoo_lim@rgei.com

Ruder Finn Asia
Senior Consultant
Sean Baker
E: bakers@ruderfinnasia.com
Mobile: +65 8875 2950

Senior Account Executive
Diane Samuel
E: samueld@ruderfinnasia.com
Mobile: +65 8863 6627

Source: International Civil Aviation Organisation